Verona Pharma

Verona Pharma Plc operates as a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. Its lead product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. The company was founded by Michael J. A. Walker and Clive P. Page on February 24, 2005 and is headquartered in London, the United Kingdom.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Verona Pharma excels in COPD trials, secures funding for growth

Verona Pharma's strong performance in Phase 3 trials and solid financial position set a positive trajectory for future growth and NDA submission.
While facing competition and addressing various challenges, the company's strategic vision and upcoming milestones offer opportunities for expansion and partnerships.

Verona Pharma reports strong Q1 earnings, gears up for ensifentrine launch

Verona Pharma's Q1 2023 earnings call highlighted strong financial performance, progress towards NDA submission for ensifentrine, and strategic initiatives for the upcoming launch.
Despite facing challenges in managing expenses and navigating regulatory processes, the company remains optimistic about its market positioning and growth prospects.
With a focus on differentiation, global partnerships, and commercial readiness, Verona Pharma is poised for success in the COPD treatment market in 2024 and beyond.
The company's emphasis on marketing, operational setup, and post-ENHANCE data promotion underscores its commitment to maximizing market impact and revenue potential.

Verona Pharma advances ensifentrine with strong Q2 performance and global expansion prospects

Verona Pharma's Q2 2023 performance showcased progress on ensifentrine and a strong financial position, despite a net loss driven by ongoing expenses.
Strengths include positive trial results, a robust cash position, and global expansion efforts, while challenges lie in financial management and regulatory uncertainties.
Opportunities abound in FDA approval prospects, market expansion through subgroup usage, reimbursement optimization, and product portfolio expansion.
Analysts' inquiries highlighted key concerns and strategic considerations for Verona Pharma's future growth and commercial success in the COPD treatment market.

Verona Pharma advances towards FDA approval with strong financials

Verona Pharma progresses towards FDA approval for ensifentrine, with a set action date.
Financially stable with cash reserves and plans for a robust sales force.
Balancing R&D investments with increased expenses and strategic challenges.
Positioned for growth with pipeline expansion and positive data on treatment impact.

Verona Pharma excels in Q4, eyes FDA approval for ensifentrine

Verona Pharma's Q4 2023 earnings call highlighted strong financials, progress with ensifentrine's FDA submission, and strategic plans for commercial launch and market positioning. While facing challenges in FDA review and commercial strategy, the company remains optimistic about ensifentrine's market prospects and growth opportunities.

Verona Pharma excels in Q1 with ensifentrine progress and financial strength

Verona Pharma's Q1 2024 performance highlighted progress on ensifentrine, strong commercial launch preparations, and a robust financial position.
Strengths lie in ensifentrine's novelty, disease awareness focus, and the company's solid financial foundation.
Challenges include addressing analyst queries, market competition, and ensuring a successful commercial launch.
Opportunities abound in leveraging ensifentrine's utility, financial strength, and the potential for market disruption in COPD treatment.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Verona Pharma Plc engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. It focuses on developing inhaled ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease. The company was founded by Michael J. A. Walker and Clive P. Page on February 24, 2005 and is headquartered in London, the United Kingdom.

Ardmore Shipping

Engie SA

Hudson Technologies

Jackson Financial

MINISO Group Holding

Modine Manufacturing

Pinduoduo Inc - ADR

Super Micro Computer

Valero Energy

Expect the unexpected has been a common theme over the past two years as global economies and markets reel from a pandemic and the war in Ukraine. June 2022 posted some of the worst performance in decades, with the S&P 500 -21%, DJIA -15%, and trillions erased since 2021 peaks, including big names like Meta, Amazon, and Google.

Top 10 Stocks For 2023

Incyte

Inspire Medical Systems Inc

Madrigal Pharmaceuticals

Schrodinger 

Veeva Systems

Viatris

With the healthcare sector poised to grow significantly in the coming years, healthcare stocks to buy present a fantastic opportunity for investors. Healthcare is something that everyone will need at some point in their lives, so today's industry of $8.3 trillion spent globally is an indication of a growing, profitable sector – one that could create many opportunities for those looking to make significant investments.

Why These 7 Healthcare Stocks Could Soar in 2023

AVEO Pharma

Cabaletta Bio

Wave Life Sciences

We present four biotech stocks, AVEO, CABA, VRNA and WVE, which despite the current volatile market, have provided more than twice the returns in 2022.

4 Drug Stocks That More Than Doubled This Year

If you are looking for stocks that are well positioned to maintain their recent uptrend, Verona Pharma PLC American Depositary Share (VRNA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Here's Why Momentum in Verona Pharma PLC American Depositary Share (VRNA) Should Keep going

Bionano Genomics

GlaxoSmithKline

iCAD

vTv Therapeutics

Choosing the best drug stocks to buy can be dicey because drug stocks have disadvantages and advantages. On the negative side, you often have to wait many years for promising drugs to prove themselves in clinical trials.

7 Drug Stocks That Will Soar in 2023

Verona Pharma (NASDAQ: VRNA ) stock is rising higher on Tuesday after the company released results from a Phase 3 clinical trial. The big news here is the company's Phase 3 ENHANCE-1 trial meeting its primary endpoint.

Why Is Verona Pharma (VRNA) Stock Up 34% Today?

Verona said Tuesday its drug significantly improved lung function in patients with COPD, and VRNA stock skyrocketed to a four-year high. The post Top-Notch Verona Pharma Scores A Win In COPD — And Hits A Four-Year High appeared first on Investor's Business Daily.

Top-Notch Verona Pharma Scores A Win In COPD — And Hits A Four-Year High

U.S.-listed shares of Verona Pharma Plc VRNA, +2.74% rallied about 39% in premarket trading on Tuesday after the company said a Phase 3 clinical trial evaluating nebulized ensifentrine as a treatment for chronic obstructive pulmonary disease met the primary and secondary endpoints. The data "support our belief that ensifentrine will change the treatment paradigm for COPD," Verona CEO David Zaccardelli said in a news release.

Verona Pharma's stock jumps 39% after sharing positive data for its COPD drug

Lucid Group

Investors hoped for a rebound in the stock market, but they might have to settle for gains in these two stocks.

Lucid Is Revving Up, but This Nasdaq Stock Is Jumping Even More

Statistically significant improvements in lung function, symptoms and quality of life

Verona Pharma Announces Ensifentrine Meets Primary and Key Secondary Endpoints in Phase 3 ENHANCE-1 Trial for COPD

LONDON and RALEIGH, N.C., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the "Company"), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces it will report top-line Phase 3 data from its ENHANCE-1 trial of nebulized ensifentrine on Tuesday, December 20, 2022. The Company will host an investment community webcast and conference call at 8:30 a.m. EST / 1:30 p.m. GMT to discuss these data.

Verona Pharma to Announce Top-line Data from Phase 3 ENHANCE-1 Trial of Nebulized Ensifentrine for COPD

Does Verona Pharma PLC American Depositary Share (VRNA) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here's Why Verona Pharma PLC American Depositary Share (VRNA) is a Great Momentum Stock to Buy

The consensus price target hints at a 95.5% upside potential for Verona Pharma PLC American Depositary Share (VRNA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts See a 95% Upside in Verona Pharma PLC American Depositary Share (VRNA): Can the Stock Really Move This High?

The mean of analysts' price targets for Verona Pharma PLC American Depositary Share (VRNA) points to a 109.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

How Much Upside is Left in Verona Pharma PLC American Depositary Share (VRNA)? Wall Street Analysts Think 110%

Verona Pharma plc (NASDAQ:VRNA ) Q3 2022 Earnings Conference Call November 9, 2022 9:00 AM ET Company Participants David Zaccardelli – Chief Executive Officer Mark Hahn – Chief Financial Officer Kathy Rickard – Chief Medical Officer Chris Martin – Senior Vice President-Commercial Conference Call Participants Suji Jeong – Jefferies Boobalan Pachaiyappan – H.C. Wainwright Tom Shrader – BTIG Operator Welcome to Verona Pharma's, Third Quarter 2022 Financial Results and Operating Highlights Conference Call.

Verona Pharma plc (VRNA) Q3 2022 Earnings Call Transcript

Access to up to $400 million expected to provide cash runway through at least 2025

Verona Pharma Reports Third Quarter 2022 Financial Results and Provides Corporate Update

LONDON and RALEIGH, N.C., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces that senior management will participate in the following conferences in November 2022:

Verona Pharma Announces November 2022 Investor Conference Participation

Assertio Therapeutics Inc

ProPhase Labs

This year's bear markets have resulted in a fall in portfolio performance. Healthcare, the second best sector this year, is defensive and has stood the test of time. The Fed's stance and volatile price swings that include declines of more than 20% in the major indexes are prompting investors to consider defensive investments.

3 Small-Cap Pharma Stocks For A 2022 Melt-Up

LONDON and RALEIGH, N.C., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the third quarter ended September 30, 2022 on Wednesday, November 9, 2022 and host an investment community conference call at 9:00 a.m. EST / 2:00 p.m. GMT to discuss these financial results and provide a corporate update.

Verona Pharma to Report Third Quarter 2022 Financial Results and Provide Corporate Update

Non-dilutive capital finances planned launch of ensifentrine for COPD Non-dilutive capital finances planned launch of ensifentrine for COPD

Verona Pharma Secures Debt Financing of up to $150 Million from Oxford Finance

LONDON and RALEIGH, N.C., Oct. 14, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces additional exacerbation* subgroup analyses from the Phase 3 ENHANCE-2 (“Ensifentrine as a Novel inHAled Nebulized COPD thErapy”) trial in chronic obstructive pulmonary disease (“COPD”). Top-line results from the trial are available on Verona Pharma's website here.

Verona Pharma Announces Analyses Demonstrating Ensifentrine Reduced Exacerbation Rates Across Subgroups in Phase 3 ENHANCE-2 Trial for COPD

Aerie Pharmaceuticals

Belite Bio Inc

Chemocentryx

Catalyst Pharmaceuticals

Akero Therapeutics Inc

Gossamer Bio Inc

Relmada Therapeutics Inc

Viridian Therapeutics

Ventyx Biosciences

The double-digit run for biotech stocks off a June bottom is great — until you realize you could've netted more by investing in the best. The post Here Are 10 Biotech Stocks — Including Catalyst And Viridian — That Would Have Netted You $10,000 More This Year appeared first on Investor's Business Daily.

Here Are 10 Biotech Stocks — Including Catalyst And Viridian — That Would Have Netted You $10,000 More This Year

Verona achieved primary and secondary endpoints in phase 3 ENHANCE-2 study using ensifentrine as maintenance treatment of COPD. Results from the second phase 3 study, ENHANCE-1, also using ensifentrine as maintenance treatment of COPD is expected by end of 2022.

Verona: Expected End Of 2022 Catalyst Could Provide Value Inflection Point

LONDON and RALEIGH, N.C., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces that senior management will present a company overview at the H.C. Wainwright 24th Annual Global Investment Conference on Monday, September 12, 2022 at 2:00 PM ET / 7:00 PM BST.

Verona Pharma to Present at H.C. Wainwright 24th Annual Global Investment Conference

LONDON and RALEIGH, N.C., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, continues its preparation for commercialization with appointments of Matthew Casbon, Vice President of Sales, Marketing and Training, and Matthew Rysavy, Vice President of Market Access and Trade. They each bring approximately 25 years of commercialization expertise spanning marketing, sales, training, market access, trade and business development across a variety of therapeutic areas.

News for Verona Pharma Stock (VRNA)